| Date | Time | Source | Headline | Symbol | Company |
| 04/25/2024 | 4:01PM | Business Wire | Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 03/07/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 03/07/2024 | 4:01PM | Business Wire | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 02/26/2024 | 9:00AM | Business Wire | Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 02/23/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 02/22/2024 | 8:30AM | Business Wire | Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 02/20/2024 | 9:00AM | Business Wire | Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 02/05/2024 | 8:30AM | PR Newswire (US) | New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 02/05/2024 | 8:30AM | Business Wire | New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 12/21/2023 | 8:00AM | Business Wire | CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 12/21/2023 | 8:00AM | PR Newswire (US) | CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 12/19/2023 | 8:01PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 12/04/2023 | 8:30AM | Business Wire | Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 11/28/2023 | 8:05AM | PR Newswire (US) | Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 11/28/2023 | 8:00AM | Business Wire | Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 11/27/2023 | 9:13AM | Dow Jones News | Arcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic Fibrosis | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 11/27/2023 | 8:30AM | Business Wire | Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 11/15/2023 | 8:51AM | IH Market News | Keep An Eye Out: Pre-Market Movers And Analyst Recommendations | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 11/14/2023 | 4:10PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 11/14/2023 | 4:01PM | Business Wire | Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 10/25/2023 | 4:01PM | Business Wire | Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 10/23/2023 | 4:01PM | Business Wire | Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 10/04/2023 | 8:30AM | Business Wire | Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 09/26/2023 | 4:06PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 09/26/2023 | 8:30AM | Business Wire | Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 09/19/2023 | 8:30AM | Business Wire | Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 09/05/2023 | 8:30AM | Business Wire | Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 08/17/2023 | 8:30AM | Business Wire | Arcturus Therapeutics to Attend Upcoming Investor Conferences | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 08/14/2023 | 9:00AM | Business Wire | Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 08/07/2023 | 5:02PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |